Novel dexamethasone formulation shows efficacy and safety with once-daily use
Eric D. Donnenfeld, a consultant to Oculis reported for Ophthalmology Times on the results of a phase 2 trial: dexamethasone
A forum for researchers, students and applicants in the field of cyclodextrin technology
Eric D. Donnenfeld, a consultant to Oculis reported for Ophthalmology Times on the results of a phase 2 trial: dexamethasone
Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases, announced
After years of slow growth, Amgen’s Kyprolis finally looks poised to break the blockbuster barrier in 2019, and new data